SCHEDULE: GSK Completes Full Divestment of CureVac Shares
Amendment to Beneficial Ownership Report
GSK plc has finalized the sale of all its common shares in CureVac N.V. through a recent Exchange Offer.
Summary
- GSK plc, through its indirect wholly-owned subsidiary Glaxo Group Limited (GGL), no longer beneficially owns any common shares of CureVac N.V.
- GGL tendered all its Common Shares in an Exchange Offer, which expired and was accepted on December 3, 2025.
- This Amendment No. 1 to Schedule 13D serves as the final amendment and constitutes an 'exit filing' for GSK regarding its investment in CureVac N.V.
- Updates were made to Schedule A to reflect current titles and honorifics of certain directors and executive officers of GSK.
Sentiment
Score: 7
Explanation: Neutral to slightly positive for GSK as it represents a clean, executed strategic exit. No negative implications are apparent from the filing itself regarding the execution of the divestment.
Positives
- GSK successfully completed its planned divestment from CureVac N.V., indicating a clear execution of its strategic portfolio management.
Future Outlook
The filing indicates GSK's complete exit from its investment in CureVac N.V., suggesting no future financial or strategic involvement with CureVac from GSK's perspective.
Management Comments
- This Amendment No. 1 is the final amendment to the Schedule 13D and constitutes an 'exit filing' for GSK.
Industry Context
This divestment by GSK from CureVac N.V. could reflect a strategic realignment within GSK's portfolio, potentially freeing up capital or optimizing its investment holdings. For CureVac, the exit of a major pharmaceutical partner like GSK could impact market perception or future collaboration prospects, depending on the nature of their prior relationship.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Various Directors and Executive Officers of GSK | NA | NA | NA | Updates to titles and honorifics in Schedule A, not actual personnel changes. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Update | Schedule A, detailing GSK's directors and executive officers, was updated to reflect changes in titles and honorifics. | NA | Minimal impact on corporate governance, primarily an administrative update to public disclosures. |
Stakeholder Impact
- Shareholders (GSK): The divestment completes a strategic move, potentially freeing up capital or streamlining GSK's portfolio.
- Shareholders (CureVac): The exit of a significant institutional holder like GSK could lead to short-term price volatility or a re-evaluation of CureVac's investor base.
Next Steps
- GSK has completed its divestment and filed an 'exit filing,' indicating no further reporting obligations under this specific Schedule 13D for CureVac N.V. shares.
Key Dates
| Date | Description |
|---|---|
| 2025-08-13 | Original Schedule 13D filed by GSK plc. |
| 2025-12-03 | Exchange Offer expired and Common Shares held by Glaxo Group Limited were accepted for exchange. |
| 2025-12-05 | Date of signing of this Amendment No. 1 to Schedule 13D. |
Keywords
GSK, CureVac, Divestment, Share Sale, Exchange Offer, Schedule 13D, Exit Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.